-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

Benzinga·08/13/2026 14:01:52
Listen to the news
Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and lowers the price target from $41 to $34.